Synthetic Biologics, Inc. (SYN) Starts Presentation at LD Micro Conference

Synthetic Biologics is developing biologics for preventing and treating serious infectious diseases. The company is developing an oral enzyme to prevent infections from Clostridium difficile, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon, and monoclonal antibody therapies for the treatment of whooping cough and other infections. The company is also developing a drug candidate for treating relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, visit the company’s website at www.syntheticbiologics.com.